These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32007507)

  • 21. A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis.
    Abelson MB; Turner D
    Clin Ther; 2003 Mar; 25(3):931-47. PubMed ID: 12852709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye.
    Mah FS; O'Brien T; Kim T; Torkildsen G
    Curr Med Res Opin; 2008 Feb; 24(2):441-7. PubMed ID: 18167176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model.
    Spangler DL; Bensch G; Berdy GJ
    Clin Ther; 2001 Aug; 23(8):1272-80. PubMed ID: 11558863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in tear function and the ocular surface after topical olopatadine treatment for allergic conjunctivitis: an open-label study.
    Dogru M; Ozmen A; Ertürk H; Sanli O; Karatas A
    Clin Ther; 2002 Aug; 24(8):1309-21. PubMed ID: 12240781
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Co-delivery of timolol and hyaluronic acid from semi-circular ring-implanted contact lenses for the treatment of glaucoma: in vitro and in vivo evaluation.
    Desai AR; Maulvi FA; Pandya MM; Ranch KM; Vyas BA; Shah SA; Shah DO
    Biomater Sci; 2018 May; 6(6):1580-1591. PubMed ID: 29708242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro and in vivo evaluation of cyclosporine-graphene oxide laden hydrogel contact lenses.
    Desai DT; Maulvi FA; Desai AR; Shukla MR; Desai BV; Khadela AD; Shetty KH; Shah DO; Willcox MDP
    Int J Pharm; 2022 Feb; 613():121414. PubMed ID: 34952149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A review of olopatadine for the treatment of ocular allergy.
    Abelson MB
    Expert Opin Pharmacother; 2004 Sep; 5(9):1979-94. PubMed ID: 15330735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis.
    Abelson MB; Gomes PJ; Pasquine T; Edwards MR; Gross RD; Robertson SM
    Allergy Asthma Proc; 2007; 28(4):427-33. PubMed ID: 17883910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.
    Avunduk AM; Tekelioglu Y; Turk A; Akyol N
    Clin Ther; 2005 Sep; 27(9):1392-402. PubMed ID: 16291412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyaluronic Acid-Pluronic®F127-Laden Soft Contact Lenses for Corneal Epithelial Healing: In Vitro and In Vivo Studies.
    Wei N; Xu X; Huang C; Cao L
    AAPS PharmSciTech; 2020 Jun; 21(5):162. PubMed ID: 32488761
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model.
    Lanier BQ; Finegold I; D'Arienzo P; Granet D; Epstein AB; Ledgerwood GL
    Curr Med Res Opin; 2004 Aug; 20(8):1227-33. PubMed ID: 15324525
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis.
    Katelaris CH; Ciprandi G; Missotten L; Turner FD; Bertin D; Berdeaux G;
    Clin Ther; 2002 Oct; 24(10):1561-75. PubMed ID: 12462286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro and in vivo evaluation of novel implantation technology in hydrogel contact lenses for controlled drug delivery.
    Maulvi FA; Lakdawala DH; Shaikh AA; Desai AR; Choksi HH; Vaidya RJ; Ranch KM; Koli AR; Vyas BA; Shah DO
    J Control Release; 2016 Mar; 226():47-56. PubMed ID: 26860285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained latanoprost release from PEGylated solid lipid nanoparticle-laden soft contact lens to treat glaucoma.
    Dang H; Dong C; Zhang L
    Pharm Dev Technol; 2022 Feb; 27(2):127-133. PubMed ID: 34704874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model.
    Berdy GJ; Stoppel JO; Epstein AB
    Clin Ther; 2002 Jun; 24(6):918-29. PubMed ID: 12117082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis.
    Rosenwasser LJ; Mahr T; Abelson MB; Gomes PJ; Kennedy K
    Allergy Asthma Proc; 2008; 29(6):644-53. PubMed ID: 19063816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model.
    Greiner JV; Udell IJ
    Clin Ther; 2005 May; 27(5):568-77. PubMed ID: 15978305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allergic conjunctivitis and contact lenses: experience with olopatadine hydrochloride 0.1% therapy.
    Brodsky M
    Acta Ophthalmol Scand Suppl; 2000; (230):56-9. PubMed ID: 11057353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model.
    Deschenes J; Discepola M; Abelson M
    Acta Ophthalmol Scand Suppl; 1999; (228):47-52. PubMed ID: 10337433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity.
    Abelson MB; Spitalny L
    Am J Ophthalmol; 1998 Jun; 125(6):797-804. PubMed ID: 9645717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.